| Trial ID: | L6502 |
| Source ID: | NCT00267683
|
| Associated Drug: |
Insulin Aspart
|
| Title: |
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin aspart|DRUG: glibenclamide
|
| Outcome Measures: |
Primary: HbA1c, after 24 weeks of treatment | Secondary: Plasma glucose levels|Percentage of subjects achieving the treatment target of HbA1c value < 6.5%
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
9
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-12
|
| Completion Date: |
2006-04
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-02
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00267683
|
